LifeMD Names Dr. Tara Scott as Ambassador and Clinical Advisor for its Women’s Health Program
LifeMD (NASDAQ: LFMD) appointed Dr. Tara Scott as ambassador and clinical advisor for its women’s health program on October 22, 2025. Dr. Scott, a board-certified OB/GYN and menopause specialist with 25+ years of clinical and teaching experience, will guide outreach, education, and program development across perimenopause, menopause, hormonal balance, bone density, metabolism, and long-term wellness.
The virtual program offers tiered subscriptions, lab access, mail-order prescriptions, dietitian support, and LifeMD+ membership with 24/7 primary and urgent care. The release cites underdiagnosis: one in four women seek menopause treatment and women represent 80% of osteoporosis cases with two-thirds undiagnosed, and references a BCG estimate of a $60–70 billion market opportunity by 2030.
LifeMD (NASDAQ: LFMD) ha nominato la Dott.ssa Tara Scott come ambasciatrice e asesor clinico per il programma di salute femminile il 22 ottobre 2025. La Dott.ssa Scott, ginecologa ostetrica certificata e specialista della menopausa con oltre 25 anni di esperienza clinica e didattica, guiderà le attività di outreach, educazione e sviluppo del programma attraverso la perimenopausa, la menopausa, l’equilibrio ormonale, la densità ossea, il metabolismo e il benessere a lungo termine.
Il programma virtuale offre abbonamenti a livelli, accesso a laboratori, prescrizioni a domicilio, supporto di una dietista e l'abbonamento LifeMD+ con assistenza primaria e urgenza 24/7. Il comunicato cita la sottodiagnosi: una donna su quattro cerca trattamento per la menopausa e le donne rappresentano l’80% dei casi di osteoporosi, con due terzi non diagnosticati, e richiama una stima di BCG di un’opportunità di mercato di 60–70 miliardi di dollari entro il 2030.
LifeMD (NASDAQ: LFMD) designó a la Dra. Tara Scott como embajadora y asesora clínica para su programa de salud femenina el 22 de octubre de 2025. La Dra. Scott, obstetra-ginecóloga certificada y especialista en menopausia con más de 25 años de experiencia clínica y docente, guiará el alcance, la educación y el desarrollo del programa en perimenopausia, menopausia, equilibrio hormonal, densidad ósea, metabolismo y bienestar a largo plazo.
El programa virtual ofrece suscripciones escalonadas, acceso a laboratorios, recetas por correo, apoyo de una dietista y la membresía LifeMD+ con atención primaria y urgente 24/7. El comunicado cita el subdiagnóstico: una de cada cuatro mujeres busca tratamiento para la menopausia y las mujeres representan el 80% de los casos de osteoporosis, con dos tercios no diagnosticados, y hace referencia a una estimación de BCG de una oportunidad de mercado de entre 60 y 70 mil millones de dólares para 2030.
LifeMD (NASDAQ: LFMD) 는 2025년 10월 22일 여성 건강 프로그램의 대사 그리고 임상 고문으로 Dr. Tara Scott를 임명했습니다. OB/GYN 및 월경전 증상 전문의인 Dr. Scott은 25년 이상의 임상 및 교육 경력을 바탕으로 산전후 관리, 월경전 및 갱년기, 호르몬 균형, 골밀도, 신진대사, 장기 건강 관리에 걸친 outreach, 교육, 프로그램 개발을 이끌어 갈 예정입니다.
가상 프로그램은 계층화된 구독, 실험실 접근, 약 처방 우편 발송, 영양사 지원, 그리고 24시간/7일 기본 진료 및 응급 진료를 제공하는 LifeMD+ 멤버십을 제공합니다. 발표는 진단 미충족을 언급합니다: 4명 중 1명이 갱년기 치료를 찾고 여성은 골다공증 사례의 80%를 차지하며 2/3는 진단되지 않는다고 하며, 2030년까지 600억-700억 달러 규모의 시장 기회에 대한 BCG의 추정치를 언급합니다.
LifeMD (NASDAQ: LFMD) a nommé le Dr Tara Scott comme ambassadrice et conseillère clinique pour son programme de santé féminine le 22 octobre 2025. Le Dr Scott, obstétricienne-gyécologue certifiée et spécialiste de la ménopause avec plus de 25 ans d’expérience clinique et d’enseignement, guidera la sensibilisation, l’éducation et le développement du programme à travers la périménopause, la ménopause, l’équilibre hormonal, la densité osseuse, le métabolisme et le bien-être à long terme.
Le programme virtuel propose des abonnements par niveaux, un accès au laboratoire, des prescriptions envoyées par courrier, un soutien diététique et l’adhésion LifeMD+ avec des soins primaires et d’urgence 24/7. Le communiqué évoque la sous-diagnostic: une femme sur quatre cherche un traitement pour la ménopause et les femmes représentent 80% des cas d’ostéoporose avec deux tiers non diagnostiqués, et il cite une estimation de BCG d’un marché potentiel de 60 à 70 milliards de dollars d’ici 2030.
LifeMD (NASDAQ: LFMD) ernannte am 22. Oktober 2025 Dr. Tara Scott zur Botschafterin und klinischen Beraterin für ihr Programm zur Frauengesundheit. Dr. Scott, eine zertifizierte Gynäkologin/ Geburtshilfe (OB/GYN) und Menopause-Spezialistin mit mehr als 25 Jahren klinischer und Lehre-Erfahrung, wird Outreach, Bildung und Programmgestaltung in den Bereichen Perimenopause, Menopause, hormonelles Gleichgewicht, Knochendichte, Stoffwechsel und langfristiges Wohlbefinden leiten.
Das virtuelle Programm bietet gestaffelte Abonnements, Laborezugang, Rezeptversand per Post, Unterstützung durch Ernährungsberaterinnen und LifeMD+ Mitgliedschaft mit 24/7 primärer und notfallmedizinischer Versorgung. Die Mitteilung verweist auf Unterdiagnose: Eine von vier Frauen sucht Behandlung für die Menopause, Frauen machen 80% der Osteoporose-Fälle aus, zwei Drittel bleiben undiagniziert, und verweist auf eine Schätzung von BCG eines Marktpotenzials von 60–70 Milliarden Dollar bis 2030.
LifeMD (NASDAQ: LFMD) عيّنت الدكتورة تارا سكوت كسفيرة ومستشارة سريرية لبرنامج صحة المرأة في LifeMD في 22 أكتوبر 2025. الدكتورة سكوت، طبيبة أمراض نساء وولادة معتمدة ومتخصصة في سن اليأس ولديها أكثر من 25 عامًا من الخبرة السريرية والتعليمية، ستقود التوعية والتعليم وتطوير البرنامج عبر فترة ما قبل سن اليأس، سن اليأس، التوازن الهرموني، كثافة العظام، الأيض والصحة طويلة الأمد.
يقدم البرنامج الافتراضي اشتراكات متدرجة، وصولاً إلى المختبرات، وصفات عبر البريد، دعم أخصائي تغذية، وعضوية LifeMD+ مع رعاية أساسية ورعاية طارئة على مدار 24/7. يشير البيان إلى انخفاض التشخيص: امرأة من بين أربع تسعى لعلاج سن اليأس، وتشكّل النساء 80% من حالات هشاشة العظام، واثنان من كل ثلاثة غير مُشخّصين، ويشير إلى تقدير BCG بوجود فرصة سوق تبلغ 60–70 مليار دولار بحلول 2030.
LifeMD (NASDAQ: LFMD) 于2025年10月22日任命 Dr. Tara Scott 为其女性健康项目的大使兼临床顾问。Scott 博士是一名获得认证的产科妇科医生（OB/GYN）和更年期专家，拥有超过25年的临床和教学经验，将指导在围绝经期、绝经期、激素平衡、骨密度、新陈代谢和长期健康方面的外展、教育和项目开发。
该虚拟项目提供分层订阅、实验室访问、邮寄处方、营养师支持，以及 LifeMD+ 会员，提供24/7初级和急诊护理。公告提到诊断不足：四分之一的女性寻求更年期治疗，女性占骨质疏松症病例的80%，其中三分之二未被诊断，并引用BCG对到2030年的60–70亿美元市场机会的估计。
- None.
- None.
Renowned Menopause and Hormone Specialist to Help Guide and Represent LifeMD’s Comprehensive and Personalized Care Offering for Women
NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the appointment of Tara Scott, MD, widely known as “The Hormone Guru,” as ambassador and clinical advisor for its comprehensive women’s health program. A respected physician, educator, and advocate, Dr. Scott will help champion LifeMD’s program while elevating public awareness around critical areas of women’s health including perimenopause, menopause, hormonal balance, bone density, metabolism, and long-term wellness.
This appointment reflects LifeMD’s commitment to building one of the most thoughtful and comprehensive women’s health offerings in the country. Dr. Scott’s voice and expertise will guide outreach, education, and program development, helping LifeMD address aspects of medicine that remain underdiagnosed and underserved.
LifeMD’s virtual women’s health program provides:
- Virtual consultations that combine clinical expertise, personalized therapies including hormone treatment, and lifestyle strategies to promote long-term health,
- A holistic approach with tiered subscriptions, including lab access, mail-order prescription fulfillment, and dietitian support, and
- LifeMD+ membership with 24/7 urgent and primary care access, prescription renewals, and a marketplace of clinically validated wellness products.
“We are honored to welcome Dr. Scott as an ambassador and advisor for LifeMD’s women’s health program,” said Jessica Friedeman, Chief Marketing and Product Officer at LifeMD. “Her leadership, deep expertise, and advocacy are perfectly aligned with our vision to elevate care for women across every stage of life. LifeMD’s women’s health initiative is designed to address the critical, often overlooked needs of women in perimenopause, menopause, and beyond. Dr. Scott’s role will ensure we continue to deliver thoughtful, clinically-supported solutions that set a new standard in accessible, expert-led care for women in their healthcare journey.”
Dr. Scott is a board-certified obstetrician/gynecologist, menopause specialist, and expert in functional and integrative medicine with more than 25 years of clinical and teaching experience. A certified menopause practitioner with The Menopause Society, she is nationally recognized for her research-backed hormonal balancing strategies and has been featured in Women’s Health, Shape, Newsweek, and other outlets. She has served as Associate Clinical Professor at Northeast Ohio Medical University and as Course Director for Women’s Health in the Integrative & Functional Medicine Fellowship at the University of California, Irvine. Dr. Scott received her medical degree from Northeast Ohio Medical University and completed her residency with Summa Health System at Akron City Hospital in Ohio.
“As a practicing clinician who has spent my career advocating for women’s health, I am honored to serve as an ambassador for LifeMD’s women’s health program,” said Dr. Scott. “LifeMD’s thoughtful approach to evidence-based, personalized care directly addresses the gaps and confusion so many women experience, particularly around menopause and hormone-related issues. This program is an opportunity to empower women with the clarity, support, and clinical expertise they need to better navigate the aging process, make informed choices, and prevent chronic disease.”
Despite growing awareness, women’s health remains one of the most underserved areas of medicine — encompassing much more than reproductive and maternity care. Menopause and osteoporosis, in particular, remain chronically underdiagnosed and undertreated: only one in four women seeks treatment for menopause-related symptoms, and while women represent
Interested patients can visit www.lifemd.com for more information.
About LifeMD, Inc.
LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women’s health, mental health, and weight management. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com.
Cautionary Note Regarding Forward Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” “predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.
Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.
Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.
Investor Contact
Marc Benathen, Chief Financial Officer
marc@lifemd.com
Media Contact
Jessica Friedeman, Chief Marketing and Product Officer
press@lifemd.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6636daf6-27dd-40ef-8b20-6cd136138ff6
FAQ
Who did LifeMD (LFMD) appoint as ambassador for its women’s health program and when?
What expertise does Dr. Tara Scott bring to LifeMD (LFMD) women’s health services?
What services are included in LifeMD’s virtual women’s health program (LFMD)?
How does LifeMD (LFMD) say the women’s health market opportunity is sized?
What underdiagnosis statistics did LifeMD cite about menopause and osteoporosis?
